Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last A$0.09 AUD
Change Today -0.002 / -2.22%
Volume 728.4K
NEU On Other Exchanges
Symbol
Exchange
OTC US
As of 9:48 PM 05/26/15 All times are local (Market data is delayed by at least 15 minutes).

neuren pharmaceuticals ltd (NEU) Snapshot

Open
A$0.09
Previous Close
A$0.09
Day High
A$0.09
Day Low
A$0.09
52 Week High
01/20/15 - A$0.19
52 Week Low
06/3/14 - A$0.06
Market Cap
146.2M
Average Volume 10 Days
1.1M
EPS TTM
A$-0.0058
Shares Outstanding
1.7B
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NEUREN PHARMACEUTICALS LTD (NEU)

Related News

No related news articles were found.

neuren pharmaceuticals ltd (NEU) Related Businessweek News

No Related Businessweek News Found

neuren pharmaceuticals ltd (NEU) Details

Neuren Pharmaceuticals Limited, a biopharmaceutical company, focuses on the development of therapies for brain injury, neurodevelopment, and neurodegenerative disorders primarily in the United States. Its products in development include Trofinetide, which is in Phase II clinical trials for use in the treatment of Rett syndrome, Fragile X syndrome, moderate to severe traumatic brain injury, and concussion; and NNZ-2591, a synthetic analogue of a naturally occurring neuropeptide that is in preclinical development for the treatment of various neurodegenerative disorders. The company has collaborative relationships with the US Army Medical Research & Materiel Command; and the Walter Reed Army Institute of Research. Neuren Pharmaceuticals Limited is based in Camberwell, Australia.

neuren pharmaceuticals ltd (NEU) Top Compensated Officers

Chief Executive Officer, Chief Science Office...
Total Annual Compensation: $493.0K
Executive Chairman
Total Annual Compensation: $512.0K
Compensation as of Fiscal Year 2013.

neuren pharmaceuticals ltd (NEU) Key Developments

Neuren Pharmaceuticals Limited, Annual General Meeting, Apr 28, 2015

Neuren Pharmaceuticals Limited, Annual General Meeting, Apr 28, 2015., at 10:30 E. Australia Standard Time. Location: Chartered Accountants Australia and New Zealand. Agenda: To consider the annual report of the company; to consider Dr. Trevor Scott be re-elected as a director of the company; to consider the approval be given to the company for the purposes of listing rule 7.1 to issue 20 million loan funded shares to Dr. Clive Blower on the terms and conditions outlined in the explanatory memorandum accompanying this notice of meeting; and to consider PricewaterhouseCoopers be re-appointed as auditor.

Neuren Pharmaceuticals Limited Reports Audited Consolidated and Parent Earnings Results for the Year Ended December 31, 2014

Neuren Pharmaceuticals Limited reported audited consolidated and parent earnings results for the year ended December 31, 2014. For the period, on consolidated basis, the company reported total revenue of AUD 4.4 million against AUD 5.0 million a year ago. Loss after tax attributable to equity holders was AUD 8.3 million against AUD 10.4 million a year ago. Net loss attributable to equity holders was AUD 8.3 million against AUD 10.4 million a year ago. Basic and diluted loss per share was AUD 0.005 against AUD 0.008 a year ago. Loss before income tax was AUD 8.32 million against AUD 10.5 million a year ago. Net cash used in operating activities was AUD 6.4 million against AUD 7.1 million a year ago. The loss decreased by AUD 2.1 million, mainly due to: An increase of AUD 1.4 million in research and development costs, with higher costs for the Rett syndrome and Fragile X syndrome clinical trials partly offset by lower costs for the Intrepid clinical trial; and A decrease of AUD 1.9 million in grant revenue from the US government, reflecting the lower costs for the Intrepid trial; offset by: An increase of AUD 0.4 million in interest income due to higher cash balances following the share placement in October 2013; Foreign exchange gains of AUD 0.9 million (2013: loss of AUD 1.4 million), mainly due to an increase in value of US dollar denominated cash balances, following the strengthening of the US dollar against the Australian dollar; and A noncash impairment loss in 2013 of AUD 2.7 million following a review of the carrying value of the acquired intellectual property related to MotivaTM. Purchase of property, plant and equipment was AUD 34,000 against AUD 16,000 a year ago. Purchase of intangible assets was AUD 3,000. For the period, on parent basis, the company reported total income of AUD 1.44 million against AUD 0.2 million a year ago. Loss after income tax was AUD 9.03 million against AUD 12.3 million a year ago. Net loss attributable to equity holders was AUD 9.03 million against AUD 12.3 million a year ago. Loss before income tax was AUD 9.03 million against AUD 12.3 million a year ago. Net cash used in operating activities was AUD 6.91 million against AUD 5.960 million a year ago. Purchase of property, plant and equipment was AUD 34,000 against AUD 16,000 a year ago. Purchase of intangible assets was AUD 3,000.

Neuren Pharmaceuticals Limited to Report Q4, 2014 Results on Feb 25, 2015

Neuren Pharmaceuticals Limited announced that they will report Q4, 2014 results on Feb 25, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NEU:AU A$0.09 AUD -0.003

NEU Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NEU.
View Industry Companies
 

Industry Analysis

NEU

Industry Average

Valuation NEU Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 46.0x
Price/Book 7.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 40.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEUREN PHARMACEUTICALS LTD, please visit www.neurenpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.